Male Hair Loss Treatment in Ukraine

In the overwhelming majority of cases there is one cause of male hair loss: an inherited sensitivity of the follicles to dihydrotestosterone. The enzyme 5-alpha reductase converts testosterone into this more active form, and in sensitive follicles it shortens the growth phase with every cycle. Hormone levels are usually normal: the issue is not the amount of androgens but the response to them, which is why a testosterone test gives no answer.

At first the hair does not fall out but becomes finer. The follicle gradually shrinks and each time produces a shorter, finer shaft, until it turns into barely visible vellus hair; this is called miniaturisation. The area is not yet bald but already "see-through", and a trichoscope shows this stage long before it is visible in the mirror.

The pattern of loss is not random. Sensitive follicles are found in the frontotemporal areas and on the crown, while those at the back and sides of the head are almost unaffected by dihydrotestosterone. This gives thinning its recognisable pattern, and hair transplantation relies on the same fact: hair from the back of the head stays insensitive in its new place. Hence a simple rule: if hair is thinning at the back and the sides, the cause is something else.

Prevalence rises by roughly ten per cent with each decade of life: about a third of men over thirty show signs, and roughly half of men over fifty, and not only in advanced stages. It can begin as early as twenty, and the earlier it starts, the further it usually progresses.

MediUkraine is a service that finds and coordinates treatment; it is not a clinic. We select the medical centre and a doctor of the right speciality, agree the appointment date and support you throughout, including if you travel from abroad. The doctor makes the diagnosis and sets the treatment regimen after an in-person examination.

The stage of male pattern baldness is described using the Norwood–Hamilton scale: seven grades, from an almost unchanged hairline to a horseshoe of hair at the back of the head and the temples. The first two are receding temporal corners, which most men develop with age and which are not considered a disease. Clinically significant thinning begins at the third: deep temporal recession and, in the crown variant, thinning at the vertex as well. At the fourth and fifth, the frontal and crown areas spread towards each other, separated by an ever thinner bridge of hair; at the sixth the bridge disappears, and at the seventh only a band at the sides and back remains.

Staging is not a formality: it determines what is possible at all. Medicines act on follicles that are still alive, even if shrunken; where the skin is smooth and the follicle openings cannot be seen, there is nothing left to act on. That is why the same regimen preserves hair for years at the third stage and changes nothing at the sixth, and this conversation should happen before you pay for a course, not a year later.

At the first and second stages treatment is usually not started. A mature hairline with receding temporal corners is a variant of normal, not the beginning of a disease, and chasing a youthful hairline with medicines is not worthwhile. The sensible step here is different: have a baseline phototrichogram and repeat it a year later. If density is stable, you simply keep monitoring; if it has dropped noticeably, you start treatment at the very beginning of the process.

The third stage is the window in which therapy achieves the most. The follicles are shrunken but alive, so some of them can return to a thicker shaft and the rest can be kept from further miniaturisation. This is where the difference between starting straight away and starting five years later becomes a visible difference in the amount of hair, and it cannot be made up later.

At the fourth and fifth stages expectations differ by zone. The crown and vertex respond better to therapy, the frontal hairline less well: miniaturisation there usually started earlier and has gone further. In practice, medicines are prescribed to preserve what is still growing behind the hairline, while the hairline itself, if it matters to you, is restored with a transplant.

At the sixth and seventh stages, the limit is the arithmetic of the donor area. The androgen-insensitive zone at the back of the head and the temples is a limited resource, roughly a few thousand grafts over a lifetime, which is not enough to cover both the front and the crown at their original density. So the conversation is not about getting the hair back but about priorities: most surgeons propose shaping the hairline that frames the face and leaving the crown alone, because a donor supply stretched across the whole head gives a sparse result everywhere.

This leaves three equally valid options, each with its own trade-offs. Therapy means daily use without gaps, monthly costs, assessing the result after six months and possible side effects. In return, it needs no surgery, works across the whole scalp, including where a transplant cannot reach, and preserves your own hair, so it will not need replacing. Its main limitation is simple: it preserves what is there rather than bringing back what has been lost.

A transplant gives a visible result that does not depend on daily discipline and does not disappear when medicines are stopped. But it does not create hair; it moves it from the back of the head, so the total amount stays the same, the donor area has to be dense, and thinning continues in the areas that were not transplanted. That is why therapy usually continues after surgery: otherwise the transplanted hairline ends up as an island next to a thinning crown.

The third option, accepting it and shaving your head, is a genuine option, not a defeat. It costs nothing each month, has no side effects and gives a predictable result from the next day, while the other two take years and have no defined end point. The downsides are real: not everyone likes the shape of their own head, the scalp needs sun protection, and you have to shave regularly. A middle ground is scalp micropigmentation, which mimics short stubble and reduces the visual contrast between hair and skin; it treats nothing, lasts several years and needs touch-ups.

Supporting treatments are assessed separately. PRP therapy has moderate evidence as an add-on to the main regimen; low-level laser therapy is backed by FDA-cleared devices and meta-analyses; scalp mesotherapy has no standardised composition or protocol, so it is not part of standard regimens. No shampoo or vitamin will stop inherited thinning. The doctor bases the decision on four factors: the stage, your age and rate of progression, donor area density, and your own expectations; if these do not match what a method can deliver, the gap is discussed before starting, not afterwards.

Hair changes at the pace of its growth cycle, so the first weeks of therapy show nothing. In weeks 2–8 minoxidil often causes a temporary increase in shedding: the medicine synchronises the cycle and pushes out shafts that were already in the resting phase. This is an expected reaction, not a deterioration, and the doctor warns about it before the first application.

The first visible changes appear after 3–4 months at the earliest, and a reliable judgement can be made after 6–12 months. Assessment is based not on impressions or the amount of hair in the drain, but on a repeat phototrichogram of the same area and photographs taken under the same lighting conditions. Without the baseline taken at the first visit, there will be nothing to compare with.

Agree in advance what counts as success. With inherited thinning, keeping the same density after a year is already a result, because without treatment it would have fallen. Roughly two in three men on systemic therapy also see partial regrowth, mostly on the crown; the frontal hairline responds less well.

If there is no change after a year, the doctor reviews the diagnosis or the regimen rather than continuing the same prescriptions. The cause may be a missed contributing factor, such as iron deficiency, a thyroid problem or irregular use of the solution, or a misidentified type of hair loss.

The main point about timing: treatment of inherited baldness has no finish line. Once the medicines are stopped, the process returns to its natural pace, and within 6–12 months the hair usually reaches the state it would have been in without therapy: what was gained over years is lost within months. That is why the question "am I ready to do this every day for the next ten years" is discussed before starting.

Follow-up examinations are scheduled at three, six and twelve months, then once a year. Patients from abroad can conveniently have interim consultations remotely: you keep the images, the report and the phototrichogram, and MediUkraine arranges a video call with the same doctor if needed.